Study to compare the effects of AZD9496 vs Fulvestrant in breast cancer. - D6090C00002

Study identifier:D6090C00002

ClinicalTrials.gov identifier:NCT03236974

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open Label, Randomised, Pre-surgical, Pharmacodynamics Study to Compare the Biological Effects of AZD9496 versus Fulvestrant in Postmenopausal Women with ER positive HER-2 negative Primary Breast Cancer

Medical condition

Postmenopausal Women with ER+ HER2- Primary Breast Cancer

Phase

Phase 1

Healthy volunteers

Study drug

Standard Arm - Fulvestrant, AZD9496

Sex

Female

Actual Enrollment

Study type

Interventional

Age

18 Years - 120 Years

Date

Study Start Date: 05 Oct 2017

Primary Completion Date: 12 Feb 2019

Study Completion Date: 12 Feb 2019

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2020 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Inclusion Criteria

1. Signed and dated informed consent form (ICF)
2. Women >=18 years
3. Patients with newly diagnosed resectable primary breast cancer scheduled to undergo treatment with curative intent by surgery
4. Histologically confirmed invasive breast cancer involving a palpable tumor of any size, or a tumor with an ultrasound assessed diameter of ≥ 1.0 cm
5. Any clinical nodal status
6. ER+breast cancer
7. HER2- breast cancer defined as a negative in situ hybridization test or an immno-histochemistry (IHC) status of 0 or 1+
8. Eastern Co-operative Oncology group (ECOG) performance status 0-1
9. Post-menopausal status defined as meeting at least one of the following criteria: Have undergone a bilateral oophorectomy; Age ≥60 years; Age ≥50 years and with cessation of regular menses ≥12 months and with an intact uterus in the absence of oral contraception or hormone-replacement therapy (HRT) prior to the diagnosis of breast cancer; Age <60 years and with cessation of regular menses ≥12 months and follicle stimulating hormone (FSH) and oestradiol levels in the postmenopausal range

Exclusion Criteria

1. Pre-treatment biopsy sample not likely to provide adequate tissue sections for the biomarker assays
2. Previous systemic or local treatment for the new primary breast cancer currently under investigation (including surgery, radiotherapy, cytotoxic and endocrine treatments)
3. Inflammatory breast cancer
4. Evidence of metastases
5. Patients currently receiving medications or herbal supplements known to be strong inhibitors/inducers of CYP3A4/5 or strong inhibitors of CYP2C8 or that are sensitive substrates of CYP2C8 inhibition
6. Concurrent treatment with other experimental drugs within 4 weeks prior to receiving study treatment
7. Use of hormone-replacement therapy from <4 weeks of the diagnostic/baseline core biopsy to the start of trial treatment
8. Patients with second primary cancer. Any endocrine therapies or other anti-cancer therapies must have been ceased at least 12 months prior to enrollment.
9. Any of the following cardiac criteria:
-Mean resting QT interval corrected for heart rate (QTc) > 470 msec obtained from 3 ECGs using Fridericia’s formula
-Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG
-Any factors that increase the risk of QTc prolongation or risk of arrhythmic events
10. Experience of any of the following in the preceding 6 months: coronary artery bypass graft (CABG), angioplasty, vascular stent, myocardial infarction (MI), angina pectoris, congestive heart failure New York Heart Association (NYHA) Grade ≥2, cerebrovascular accident (CVA), transient ischaemic attack (TIA), deep venous or arterial thrombosis, pulmonary embolism, bleeding diathesis (i.e., disseminated intravascular coagulation, clotting factor deficiency) or requirement of anticoagulant therapy
11. As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases,
12. Uncontrolled symptomatic thyroid dysfunction (hyperthyroidism or hypothyroidism).
13. Unexplained symptomatic endometrial disorders.
14. Refractory nausea and vomiting, uncontrolled chronic GI diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD9496.
15. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: absolute neutrophil count < 1.5 x 109/L, Platelet count < 100 x 109/L, Haemoglobin < 90 g/L, alanine aminotransferase (ALT) > 2.5x upper limit of normal (ULN), aspartate aminotransferase (AST) > 2.5 x ULN, Total bilirubin > 1.5 x ULN or > 3 x in case of Gilbert’s Syndrome, glomerular filtration rate < 50 mL/min
16. Direct involvement in the planning and conduct of the study
17. History of hypersensitivity to AZD9496
18. History of hypersensitivity to fulvestrant and/or castor oil
19. Judgment by the investigator that the patient should not participate in the study if unlikely to comply with study procedures, restrictions and requirements
In addition, the following is considered a criterion for exclusion from the exploratory genetic research: Previous allogeneic bone marrow transplant; Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection

No locations available

Arms	Assigned Interventions
Active Comparator: Standard arm Fulvestrant, 500 mg	Drug: Standard Arm - Fulvestrant 500 mg Fulvestrant administered as two consecutive 5 ml intramuscular injections on Day 1, one in each buttock Other Name: Fulvestrant
Experimental: AZD9496 250 mg bd taken orally for 5-14 days	Drug: AZD9496 Administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy Other Name: Study drug

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]